Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 -4.15%75 Debt-to-Equity is 0.11 as of Jun. 2026, which is at its 10-year median of 0.11. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Mentice AB ranks better than 66.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Mentice AB's Debt-to-Equity or its related term are showing as below:
FRA:MN2'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.11 Max: 0.33
Current: 0.11
During the past 9 years, the highest Debt-to-Equity Ratio of Mentice AB was 0.33. The lowest was 0.03. And the median was 0.11.
FRA:MN2's Debt-to-Equity is ranked better than 66.48% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:MN2: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Mentice AB Debt-to-Equity Related Terms
Mentice AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Mentice AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MN2 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Mentice AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Mentice AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a Debt-to-Equity of 0.11 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mentice AB and its competitors. This is near median its historical median of 0.11. Over the past decade, Mentice AB's Debt-to-Equity has ranged from 0.03 to 0.33. According to the industry distribution chart, Mentice AB ranks #236 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 33.5%.
Is Mentice AB's Debt-to-Equity too high?
Mentice AB's current Debt-to-Equity of 0.11 is near median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.33. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Mentice AB's value of 0.11 is 52.2% below this industry median. Based on the distribution chart, Mentice AB ranks #236 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #236 out of 704 companies for Debt-to-Equity. This puts Mentice AB in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Mentice AB's value of 0.11 is 52.2% below this benchmark. Historically, Mentice AB's own Debt-to-Equity has ranged from 0.03 to 0.33 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 0.23, Mentice AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current Debt-to-Equity of 0.11 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Debt-to-Equity is 0.11, which is near median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.91, compared to a current price of €1.27 — trading 33.5% below its estimated fair value. The current Debt-to-Equity is 0.11, which is near median its 10-year median of 0.11 and 52.2% below the Medical Devices & Instruments industry median of 0.23. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current Debt-to-Equity is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.27 is trading 33.5% below its estimated GF Value™ of €1.91.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
Debt-to-Equity: 0.11 (near median its 10-year median of 0.11)
GF Value™: €1.91 vs. price of €1.27 (33.5% below fair value)
Industry Position: 52.2% below the Medical Devices & Instruments median (#236 of 704)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
